keratin antibody in serum
Jump to navigation
Jump to search
Indications
- evaluation of rheumatoid arthritis
Clinical significance
- 36-59% of patients with rheumatoid arthritis have anti-keratin antibody compared with 0-3% of healthy individuals
- anti-keratin antibody specificity
- AE1/AE3: pankeratin
- AE1: CK10/CK11/CK13/CK14/CK15/CK16/CK19 (low molecular weight keratins)
- AE3: high molecular weight keratins
- CAM5.2: anti-keratin 8/18
- 35 beta H11: anti-keratin 18
- 34 beta E12 (CK903): CK1/CK5/CK10/CK14
- basal cell specific
- basal cells of prostate
- spurious keratin immunoreactivity has been described in glial cells & neoplasms with AE1/AE3 & 34 beta E12 antibodies.
- CAM 5.2 does not react with astroglial cells
Methods
- anti-keratin antibodies react against the stratum corneum of rat esophagus